The fact
The approval targets non-alcoholic steatohepatitis, a growing market in the Middle East.
This milestone paves the way for commercialization in the kingdom starting in 2026.
Click the link to read an article on the topic:
The approval targets non-alcoholic steatohepatitis, a growing market in the Middle East.
This milestone paves the way for commercialization in the kingdom starting in 2026.